Javlor

Vinflunine, the active ingredient in Javlor, is a Vinca alkaloid (microtubule inhibitor) presented as an intravenous solution for intravenous use. It is indicated for patients with advanced or metastatic urothelial carcinoma who have progressed after platinum‑based chemotherapy, offering a targeted antineoplastic option in later‑line treatment.

GNH USA supplies Javlor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with established cold‑chain logistics and regulatory support for cross‑border distribution. Our team ensures product integrity and timely delivery to meet clinical demand.

Vinflunine is employed in the treatment of urothelial carcinoma, a cancer of the urinary tract.

Advanced or metastatic urothelial carcinoma: provides a therapeutic option after failure of platinum‑based chemotherapy to achieve disease control, potentially extending progression‑free survival and offering an additional line of therapy. Platinum‑refractory urothelial carcinoma: serves as a later‑line treatment when standard platinum regimens are no longer effective, giving clinicians an alternative antineoplastic strategy.

Vinflunine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Constipation: decreased bowel motility causing discomfort. - Nausea and vomiting: gastrointestinal upset often requiring anti‑emetics. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss that may be temporary.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe hemorrhage: bleeding complications due to platelet suppression. - Hepatic toxicity: elevated liver enzymes indicating liver injury. - Renal impairment: decreased kidney function necessitating monitoring. - Anaphylactic reactions: rare severe allergic responses needing immediate treatment.

Vinflunine requires careful monitoring and specific safety measures before and during therapy.

Monitor blood counts: perform regular complete blood counts to detect neutropenia or anemia. Assess renal function: evaluate creatinine clearance prior to each infusion. Evaluate hepatic function: check liver enzymes and bilirubin levels regularly. Avoid use in severe neutropenia: do not administer if absolute neutrophil count is critically low. Use with caution in elderly patients: consider dose adjustments and close observation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Vinflunine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinflunine exposure and toxicity. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce vinflunine plasma levels. - Antiemetics such as ondansetron: potential QT‑interval prolongation, monitor ECG. - Warfarin: possible alteration of INR, require regular coagulation monitoring.